Minhai COVID-19 vaccine ( zh, s=康泰民海新冠疫苗), trademarked as KCONVAC ( zh, s=可维克, p=Kěwéikè), is a

COVID-19 vaccine A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 ( COVID19). Prior to the COVID19 pandemic, an e ...

developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

Clinical trials

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China. Later, KCONVAC started phase II trials with 1,000 participants in China. In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.

Children and adolescents trials

In August 2021, KCONVAC started phase I trials with 84 participants in China. In September, KCONVAC started phase II trials with 480 participants in China.

Authorizations

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.

References

Chinese COVID-19 vaccines Inactivated vaccines Science and technology in China {{COVID19-vaccine-stub